Translocated HMGB3 is involved in papillary thyroid cancer progression by activating cytoplasmic TLR3 and transmembrane TREM1

References

• Cancer IAfRo. IARC Biennial Report 2020-2021. Lyon: International Agency for Research on Cancer; 2021.
   Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Magarey MJ, Freeman JL. Recurrent well-differentiated thyroid carcinoma. Oral Oncol. 2013;49(7):689–694. doi: 10.1016/j.oraloncology.2013.03.434
   PubMed Web of Science ®Google Scholar
• Brassard M, Borget I, Edet-Sanson A, et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab. 2011;96(5):1352–9. doi: 10.1210/jc.2010-2708
   PubMed Web of Science ®Google Scholar
• Cunha LL, Ward LS. Translating the immune microenvironment of thyroid cancer into clinical practice. Endocr Relat Cancer. 2022;29(6):R67–R83. doi: 10.1530/ERC-21-0414
   PubMed Web of Science ®Google Scholar
• Menicali E, Guzzetti M, Morelli S, et al. Immune landscape of thyroid cancers: new insights. Front Endocrinol. 2020;11:637826. doi: 10.3389/fendo.2020.637826
   PubMed Web of Science ®Google Scholar
• Chen R, Kang R, Tang D. The mechanism of HMGB1 secretion and release. Exp Mol Med. 2022;54(2):91–102. doi: 10.1038/s12276-022-00736-w
   PubMed Web of Science ®Google Scholar
• Lange SS, Mitchell DL, Vasquez KM. High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage. Proc Natl Acad Sci USA. 2008;105(30):10320–5. doi: 10.1073/pnas.0803181105
   PubMed Web of Science ®Google Scholar
• Ueda T, Yoshida M. HMGB proteins and transcriptional regulation. Biochim Biophys Acta. 2010;1799(1–2):114–8. doi: 10.1016/j.bbagrm.2009.11.005
   PubMed Web of Science ®Google Scholar
• Yanai H, Ban T, Wang Z, et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature. 2009;462(7269):99–103. doi: 10.1038/nature08512
   PubMed Web of Science ®Google Scholar
• Livesey KM, Kang R, Vernon P, et al. p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res. 2012;72(8):1996–2005. doi: 10.1158/0008-5472.CAN-11-2291
   PubMed Web of Science ®Google Scholar
• An Y, Zhang Z, Shang Y, et al. miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis. 2015;6(5):e1766. doi: 10.1038/cddis.2015.123
   PubMedGoogle Scholar
• Liu X, Wu J, Fan M, et al. Novel dihydroartemisinin derivative DHA-37 induces autophagic cell death through upregulation of HMGB1 in A549 cells. Cell Death Dis. 2018;9(11):1048. doi: 10.1038/s41419-018-1006-y
   PubMedGoogle Scholar
• Chai W, Ye F, Zeng L, et al. HMGB1-mediated autophagy regulates sodium/iodide symporter protein degradation in thyroid cancer cells. J Exp Clin Cancer Res. 2019;38(1):325. doi: 10.1186/s13046-019-1328-3
   PubMedGoogle Scholar
• Yanai H, Ban T, Taniguchi T. High-mobility group box family of proteins: ligand and sensor for innate immunity. Trends Immunol. 2012;33(12):633–40. doi: 10.1016/j.it.2012.10.005
   PubMed Web of Science ®Google Scholar
• Pusterla T, de Marchis F, Palumbo R, et al. High mobility group B2 is secreted by myeloid cells and has mitogenic and chemoattractant activities similar to high mobility group B1. Autoimmunity. 2009;42(4):308–10. doi: 10.1080/08916930902831845
   PubMed Web of Science ®Google Scholar
• Min HJ, Park JS, Kim KS, et al. Th2 cytokines-DUOX2-ROS-HMGB1 translocation axis is important in the pathogenesis of allergic rhinitis. Clin Sci (Lond). 2021;135(3):483–94. doi: 10.1042/CS20201212
   PubMed Web of Science ®Google Scholar
• Min HJ, Kim JH, Yoo JE, et al. ROS-dependent HMGB1 secretion upregulates IL-8 in upper airway epithelial cells under hypoxic condition. Mucosal Immunol. 2017;10(3):685–94. doi: 10.1038/mi.2016.82
   PubMed Web of Science ®Google Scholar
• Yang Y, Yang L, Jiang S, et al. HMGB1 mediates lipopolysaccharide-induced inflammation via interacting with GPX4 in colon cancer cells. Cancer Cell Int. 2020;20(1):205. doi: 10.1186/s12935-020-01289-6
   PubMed Web of Science ®Google Scholar
• Pusterla T, Nemeth J, Stein I, et al. Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice. Hepatology. 2013;58(1):363–73. doi: 10.1002/hep.26395
   PubMed Web of Science ®Google Scholar
• Jia L, Clear A, Liu FT, et al. Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood. 2014;123(11):1709–19. doi: 10.1182/blood-2013-10-529610
   PubMed Web of Science ®Google Scholar
• He S, Cheng J, Sun L, et al. HMGB1 released by irradiated tumor cells promotes living tumor cell proliferation via paracrine effect. Cell Death Dis. 2018;9(6):648. doi: 10.1038/s41419-018-0626-6
   PubMed Web of Science ®Google Scholar
• van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, et al. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene. 2013;32(3):363–374. doi: 10.1038/onc.2012.49
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Seya T. TLR3: interferon induction by double-stranded RNA including poly(I: C). Adv Drug Deliv Rev. 2008;60(7):805–812. doi: 10.1016/j.addr.2007.11.005
   PubMed Web of Science ®Google Scholar
• Omagari D, Takenouchi-Ohkubo N, Endo S, et al. Nuclear factor kappa B plays a pivotal role in polyinosinic-polycytidylic acid-induced expression of human β-defensin 2 in intestinal epithelial cells. Clin Exp Immunol. 2011;165(1):85–93. doi: 10.1111/j.1365-2249.2011.04404.x
   PubMed Web of Science ®Google Scholar
• Fu J, Lv H, Guan H, et al. Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway. BMC Cancer. 2013;13(1):462. doi: 10.1186/1471-2407-13-462
   PubMedGoogle Scholar
• Deng X, Fu J, Song Y, et al. Glucocorticoid receptor dysfunction orchestrates inflammasome effects on chronic obstructive pulmonary disease-induced depression: a potential mechanism underlying the cross talk between lung and brain. Brain Behav Immun. 2019;79:195–206. doi: 10.1016/j.bbi.2019.02.001
   PubMed Web of Science ®Google Scholar
• Hung SC, Pochampally RR, Chen SC, et al. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells. 2007;25(9):2363–70. doi: 10.1634/stemcells.2006-0686
   PubMed Web of Science ®Google Scholar
• Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8(3):138–140.
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1–6. doi: 10.1016/S1476-5586(04)80047-2
   PubMed Web of Science ®Google Scholar
• Calvano SE, Xiao W, Richards DR, et al. A network-based analysis of systemic inflammation in humans. Nature. 2005;437(7061):1032–7. doi: 10.1038/nature03985
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhang C, Zhu Y, et al. TREM1 fosters an immunosuppressive tumor microenvironment in papillary thyroid cancer. Endocr Relat Cancer. 2022;29(2):71–86. doi: 10.1530/ERC-21-0297
   PubMed Web of Science ®Google Scholar
• Duan M, Wang ZC, Wang XY, et al. TREM-1, an inflammatory modulator, is expressed in hepatocellular carcinoma cells and significantly promotes tumor progression. Ann Surg Oncol. 2015;22(9):3121–9. doi: 10.1245/s10434-014-4191-7
   PubMed Web of Science ®Google Scholar
• Arts RJ, Joosten LA, van der Meer JW, et al. TREM-1: intracellular signaling pathways and interaction with pattern recognition receptors. J Leukocyte Biol. 2013;93(2):209–215. doi: 10.1189/jlb.0312145
   PubMed Web of Science ®Google Scholar
• Gibot S, Kolopp-Sarda MN, Bene MC, et al. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J Exp Med. 2004;200(11):1419–1426. doi: 10.1084/jem.20040708
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Signaling to NF-κB by Toll-like receptors. Trends Mol Med. 2007;13(11):460–469. doi: 10.1016/j.molmed.2007.09.002
   PubMed Web of Science ®Google Scholar
• Li D, Gu R, Yang X, et al. TLR3 correlated with cervical lymph node metastasis in patients with papillary thyroid cancer. Int J Clin Exp Med. 2014;7(12):5111–5117.
   PubMed Web of Science ®Google Scholar
• McCall KD, Harii N, Lewis CJ, et al. High basal levels of functional toll-like receptor 3 (TLR3) and noncanonical Wnt5a are expressed in papillary thyroid cancer and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. Endocrinology. 2007;148(9):4226–37. doi: 10.1210/en.2007-0459
   PubMed Web of Science ®Google Scholar
• Peng S, Li C, Wang X, et al. Increased toll-like receptors activity and TLR ligands in patients with autoimmune thyroid diseases. Front Immunol. 2016;7:578. doi: 10.3389/fimmu.2016.00578
   PubMed Web of Science ®Google Scholar
• Niu L, Yang W, Duan L, et al. Biological functions and theranostic potential of HMGB family members in human cancers. Ther Adv Med Oncol. 2020;12:1758835920970850. doi: 10.1177/1758835920970850
   Web of Science ®Google Scholar
• Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18(5):309–324. doi: 10.1038/nri.2017.142
   PubMed Web of Science ®Google Scholar
• Stros M. HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta. 2010;1799(1–2):101–13. doi: 10.1016/j.bbagrm.2009.09.008
   PubMed Web of Science ®Google Scholar
• Mardente S, Mari E, Consorti F, et al. HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells. Oncol Rep. 2012;28(6):2285–9. doi: 10.3892/or.2012.2058
   PubMed Web of Science ®Google Scholar
• Mardente S, Mari E, Massimi I, et al. HMGB1-induced cross talk between PTEN and miRs 221/222 in thyroid cancer. Biomed Res Int. 2015;2015:512027. doi: 10.1155/2015/512027
   PubMed Web of Science ®Google Scholar
• Run L, Wang L, Nong X, et al. Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy. Endocrine. 2021;71(2):418–26. doi: 10.1007/s12020-020-02417-y
   PubMed Web of Science ®Google Scholar
• Hou P, Liu D, Xing M. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr Relat Cancer. 2011;18(6):687–97. doi: 10.1530/ERC-11-0212
   PubMed Web of Science ®Google Scholar
• Dong S, Pan J, Shen YB, et al. SYT7 plays a role in promoting thyroid cancer by mediating HMGB3 ubiquitination. Endocr Relat Cancer. 2022;29(4):175–89. doi: 10.1530/ERC-21-0146
   PubMed Web of Science ®Google Scholar
• Hubert P, Roncarati P, Demoulin S, et al. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. J Immunother Cancer. 2021;9(3):e001966. doi: 10.1136/jitc-2020-001966
   PubMed Web of Science ®Google Scholar
• Liu Y, Yan W, Tohme S, et al. Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. J Hepatol. 2015;63(1):114–21. doi: 10.1016/j.jhep.2015.02.009
   PubMed Web of Science ®Google Scholar
• Mortezaee K, Majidpoor J. The impact of hypoxia on immune state in cancer. Life Sci. 2021;286:120057. doi: 10.1016/j.lfs.2021.120057
   PubMed Web of Science ®Google Scholar
• Chang WH, Lai AG. The hypoxic tumour microenvironment: A safe haven for immunosuppressive cells and a therapeutic barrier to overcome. Cancer Lett. 2020;487:34–44. doi: 10.1016/j.canlet.2020.05.011
   PubMed Web of Science ®Google Scholar
• D’Ignazio L, Bandarra D, Rocha S. NF -κB and HIF crosstalk in immune responses. FEBS J. 2016;283(3):413–424. doi: 10.1111/febs.13578
   PubMed Web of Science ®Google Scholar
• D’Ignazio L, Batie M, Rocha S. Hypoxia and inflammation in cancer, focus on HIF and NF-κB. Biomedicines. 2017;5(2):21. doi: 10.3390/biomedicines5020021
   PubMed Web of Science ®Google Scholar
• Tafani M, De Santis E, Coppola L, et al. Bridging hypoxia, inflammation and estrogen receptors in thyroid cancer progression. Biomed Pharmacother. 2014;68(1):1–5. doi: 10.1016/j.biopha.2013.10.013
   PubMed Web of Science ®Google Scholar
• Yanai H, Ban T, Taniguchi T. Essential role of high-mobility group box proteins in nucleic acid-mediated innate immune responses. J Intern Med. 2011;270(4):301–8. doi: 10.1111/j.1365-2796.2011.02433.x
   PubMed Web of Science ®Google Scholar
• Lim KH, Staudt LM. Toll-like receptor signaling. Cold Spring Harb Perspect Biol. 2013;5(1):a011247. doi: 10.1101/cshperspect.a011247
   PubMed Web of Science ®Google Scholar
• Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol. 2000;164(10):4991–5. doi: 10.4049/jimmunol.164.10.4991
   PubMed Web of Science ®Google Scholar
• Fontana R, Raccosta L, Rovati L, et al. Nuclear receptor ligands induce TREM-1 expression on dendritic cells: analysis of their role in tumors. Oncoimmunology. 2019;8(3):1554967. doi: 10.1080/2162402X.2018.1554967
   PubMed Web of Science ®Google Scholar
• Wu Q, Zhou W, Yin S, et al. Blocking triggering receptor expressed on myeloid cells-1-positive tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-programmed cell death ligand 1 resistance in liver cancer. Hepatology. 2019;70(1):198–214. doi: 10.1002/hep.30593
   PubMed Web of Science ®Google Scholar
• Cioni B, Zaalberg A, van Beijnum JR, et al. Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion. Nat Commun. 2020;11(1):4498. doi: 10.1038/s41467-020-18313-y
   PubMed Web of Science ®Google Scholar
• Molgora M, Esaulova E, Vermi W, et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. Cell. 2020;182(4):886–900 e17. doi: 10.1016/j.cell.2020.07.013
   PubMed Web of Science ®Google Scholar